Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T88360
(Former ID: TTDI02133)
|
|||||
| Target Name |
Respiratory syncytial virus protein N (RSV N)
|
|||||
| Synonyms |
RSV Protein N; RSV Nucleoprotein; RSV Nucleocapsid protein; N
Click to Show/Hide
|
|||||
| Gene Name |
RSV N
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Viral encephalitis [ICD-11: 1C80] | |||||
| 2 | Virus infection [ICD-11: 1A24-1D9Z] | |||||
| Function |
Encapsidates the genome, protecting it from nucleases. The nucleocapsid (NC) has a helical structure. The encapsidated genomic RNA is termed the NC and serves as template for transcription and replication. During replication, encapsidation by protein N is coupled to RNA synthesis and all replicative products are resistant to nucleases.
Click to Show/Hide
|
|||||
| BioChemical Class |
Paramyxoviruses nucleocapsid
|
|||||
| UniProt ID | ||||||
| Sequence |
MALSKVKLNDTLNKDQLLSSSKYTIQRSTGDSIDTPNYDVQKHINKLCGMLLITEDANHK
FTGLIGMLYAMSRLGREDTIKILRDAGYHVKANGVDVTTHRQDINGKEMKFEVLTLASLT TEIQINIEIESRKSYKKMLKEMGEVAPEYRHDSPDCGMIILCIAALVITKLAAGDRSGLT AVIRRANNVLKNEMKRYKGLLPKDIANSFYEVFEKHPHFIDVFVHFGIAQSSTRGGSRVE GIFAGLFMNAYGAGQVMLRWGVLAKSVKNIMLGHASVQAEMEQVVEVYEYAQKLGGEAGF YHILNNPKASLLSLTQFPHFSSVVLGNAAGLGIMGEYRGTPRNQDLYDAAKAYAEQLKEN GVINYSVLDLTAEELEAIKHQLNPKDNDVEL Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | EDP-938 | Drug Info | Phase 2 | Respiratory syncytial virus infection | [2] | |
| 2 | RSV-604 | Drug Info | Phase 2 | Virus infection | [1] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 2 Inhibitor drugs | + | ||||
| 1 | EDP-938 | Drug Info | [3] | |||
| 2 | RSV-604 | Drug Info | [1] | |||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: L-phenylalanine | Ligand Info | |||||
| Structure Description | N-terminal globular domain of the RSV Nucleoprotein in complex with C- terminal phenylalanine of the Phosphoprotein | PDB:4UC8 | ||||
| Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | No | [4] |
| PDB Sequence |
SIDTPNYDVQ
41 KHINKLCGML51 LITEDANHKF61 TGLIGMLYAM71 SRLGREDTIK81 ILRDAGYHVK 91 ANGVDVTTHR101 QDINGKEMKF111 EVLTLASLTT121 EIQINIEIES131 RKSYKKMLKE 141 MGEVAPEYRH151 DSPDCGMIIL161 CIAALVITKL171 AAGDRSGLTA181 VIRRANNVLK 191 NEMKRYKGLL201 PKDIANSFYE211 VFEKHPHFID221 VFVHFGIAQS231 STKGGSRVEG 241 IFAGLFMNAY251 GL
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
| Ligand Name: L-aspartic acid | Ligand Info | |||||
| Structure Description | N-terminal globular domain of the RSV Nucleoprotein in complex with C- terminal dipeptide of the Phosphoprotein | PDB:4UC9 | ||||
| Method | X-ray diffraction | Resolution | 2.40 Å | Mutation | No | [4] |
| PDB Sequence |
SIDTPNYDVQ
41 KHINKLCGML51 LITEDANHKF61 TGLIGMLYAM71 SRLGREDTIK81 ILRDAGYHVK 91 ANGVDVTTHR101 QDINEMKFEV113 LTLASLTTEI123 QINIEIESRK133 SYKKMLKEMG 143 EVAPEYRHDS153 PDCGMIILCI163 AALVITKLAA173 GDRSGLTAVI183 RRANNVLKNE 193 MKRYKGLLPK203 DIANSFYEVF213 EKHPHFIDVF223 VHFGIAQSST233 RGGSRVEGIF 243 AGLFMNAYG
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7. | |||||
| REF 2 | ClinicalTrials.gov (NCT04816721) A Study to Evaluate EDP 938 Regimens in Infants With RSV (RSVPEDs). U.S. National Institutes of Health. | |||||
| REF 3 | EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog. 2021 Mar 15;17(3):e1009428. | |||||
| REF 4 | A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus. J Virol. 2015 Nov;89(21):11129-43. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.